Fasting Study of Alendronate Sodium Tablets (70 mg) and Fosamax Tablets (70 mg)
Status:
Completed
Trial end date:
2002-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the bioequivalence of Mylan's alendronate
sodium 70 mg tablets to Merck's Fosamax 70 mg tablets following a single, oral 70 mg (1 x 70
mg) dose administration under fasting conditions.